Akari Therapeutics (NASDAQ:AKTX) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research note published on Tuesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Price Performance

Shares of NASDAQ AKTX opened at $1.16 on Tuesday. The stock has a fifty day simple moving average of $1.97 and a two-hundred day simple moving average of $2.73. Akari Therapeutics has a 1-year low of $1.10 and a 1-year high of $5.50.

Hedge Funds Weigh In On Akari Therapeutics

Large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its stake in Akari Therapeutics by 411.4% during the first quarter. Renaissance Technologies LLC now owns 283,550 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 228,100 shares during the period. Cerity Partners LLC bought a new stake in Akari Therapeutics during the second quarter valued at $55,000. LPL Financial LLC bought a new stake in Akari Therapeutics during the second quarter valued at $83,000. Omnia Family Wealth LLC boosted its stake in Akari Therapeutics by 48.2% during the fourth quarter. Omnia Family Wealth LLC now owns 87,628 shares of the biopharmaceutical company’s stock valued at $273,000 after buying an additional 28,511 shares during the period. Finally, Sabby Management LLC boosted its stake in Akari Therapeutics by 116.5% during the first quarter. Sabby Management LLC now owns 7,941,867 shares of the biopharmaceutical company’s stock valued at $1,443,000 after buying an additional 4,273,528 shares during the period. 5.06% of the stock is owned by institutional investors.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.